SG Americas Securities LLC lowered its stake in Fresenius Medical Care Corporation (NYSE:FMS) by 47.4% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 16,331 shares of the company’s stock after selling 14,708 shares during the period. SG Americas Securities LLC’s holdings in Fresenius Medical Care were worth $798,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Fragasso Group Inc. increased its position in shares of Fresenius Medical Care by 11.4% in the 3rd quarter. Fragasso Group Inc. now owns 23,139 shares of the company’s stock worth $1,131,000 after purchasing an additional 2,375 shares during the last quarter. Comerica Bank boosted its holdings in shares of Fresenius Medical Care by 4.1% in the 3rd quarter. Comerica Bank now owns 47,848 shares of the company’s stock valued at $2,317,000 after buying an additional 1,876 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Fresenius Medical Care by 4.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 53,263 shares of the company’s stock valued at $2,604,000 after buying an additional 2,429 shares during the period. Toronto Dominion Bank acquired a new position in shares of Fresenius Medical Care in the 3rd quarter valued at about $277,000. Finally, Cambiar Investors LLC boosted its holdings in shares of Fresenius Medical Care by 3.8% in the 3rd quarter. Cambiar Investors LLC now owns 2,695,714 shares of the company’s stock valued at $131,793,000 after buying an additional 99,234 shares during the period. 3.03% of the stock is owned by institutional investors.
Several research analysts have recently commented on FMS shares. Royal Bank of Canada reaffirmed a “hold” rating and issued a $44.00 price target on shares of Fresenius Medical Care in a report on Wednesday, September 13th. Zacks Investment Research lowered shares of Fresenius Medical Care from a “buy” rating to a “sell” rating in a research note on Wednesday, October 25th. Morgan Stanley lowered shares of Fresenius Medical Care from an “overweight” rating to an “equal weight” rating in a research note on Monday. Finally, DZ Bank reissued a “buy” rating on shares of Fresenius Medical Care in a research note on Monday, November 13th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $48.50.
Shares of Fresenius Medical Care Corporation (FMS) traded down $0.68 during trading hours on Friday, hitting $51.52. 101,000 shares of the stock were exchanged, compared to its average volume of 179,888. The firm has a market cap of $32,140.69, a price-to-earnings ratio of 23.41, a P/E/G ratio of 2.35 and a beta of 0.45. Fresenius Medical Care Corporation has a 12 month low of $39.46 and a 12 month high of $52.38. The company has a current ratio of 1.22, a quick ratio of 0.98 and a debt-to-equity ratio of 0.55.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/15/fresenius-medical-care-corporation-fms-shares-sold-by-sg-americas-securities-llc.html.
Fresenius Medical Care Profile
Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.
Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.